BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365 [PMID: 31988594 DOI: 10.3748/wjg.v26.i3.353] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Winter J, Lenders MM, Gassenmaier M, Forschner A, Leiter U, Weide B, Purde MT, Flatz L, Cozzio A, Röcken M, Garbe C, Eigentler TK, Wagner NB. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:1089-99. [PMID: 33113003 DOI: 10.1007/s00262-020-02768-5] [Reference Citation Analysis]
2 Clinton JW, Kiparizoska S, Aggarwal S, Woo S, Davis W, Lewis JH. Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug Saf 2021;44:1125-49. [PMID: 34533782 DOI: 10.1007/s40264-021-01109-4] [Reference Citation Analysis]
3 Sato K, Hayashi M, Abe K, Fujita M, Takahashi A, Ohira H. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report. Clin J Gastroenterol 2020;13:1310-4. [PMID: 32643124 DOI: 10.1007/s12328-020-01178-5] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Björnsson ES, Andrade RJ. Long-term sequelae of Drug-induced liver injury. J Hepatol 2021:S0168-8278(21)02118-8. [PMID: 34688732 DOI: 10.1016/j.jhep.2021.10.011] [Reference Citation Analysis]
5 Takinami M, Ono A, Kawabata T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Endo M, Kiyohara Y, Yasui H, Niwakawa M, Takahashi T. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs 2021. [PMID: 34046801 DOI: 10.1007/s10637-021-01136-z] [Reference Citation Analysis]
6 Ziogas DC, Gogas H. Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al. J Immunother Cancer 2021;9:e002391. [PMID: 33737346 DOI: 10.1136/jitc-2021-002391] [Reference Citation Analysis]
7 Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, Yang X. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug Des Devel Ther 2020;14:3625-49. [PMID: 32982171 DOI: 10.2147/DDDT.S267433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Gauci ML, Baroudjian B, Lebbe C, Roux O. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer 2021;9:e002337. [PMID: 33771893 DOI: 10.1136/jitc-2021-002337] [Reference Citation Analysis]
9 Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Target Oncol 2020;15:449-66. [PMID: 32725437 DOI: 10.1007/s11523-020-00738-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
10 Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. [PMID: 34172516 DOI: 10.1136/jitc-2021-002435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Talbot S, MacLaren V, Lafferty H. Sclerosing cholangitis in a patient treated with nivolumab. BMJ Case Rep 2021;14:e241700. [PMID: 34049893 DOI: 10.1136/bcr-2021-241700] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ooi R, Tobino K, Sakabe M, Kawabata T, Hiramatsu Y, Sueyasu T, Yoshimine K. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. Respir Med Case Rep 2020;31:101197. [PMID: 32944497 DOI: 10.1016/j.rmcr.2020.101197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 McClure T, Cui W, Asadi K, John T, Testro A. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up. BMJ Open Gastroenterol 2020;7:e000487. [PMID: 32912846 DOI: 10.1136/bmjgast-2020-000487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Nabeshima S, Yamasaki M, Matsumoto N, Takaki S, Nishi Y, Kawamoto K, Taniwaki M, Ohashi N, Hattori N. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report. Cancer Treat Res Commun 2021;26:100270. [PMID: 33338849 DOI: 10.1016/j.ctarc.2020.100270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Matsumoto S, Watanabe K, Kobayashi N, Irie K, Yamanaka S, Kaneko T. Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient. Respirol Case Rep 2020;8:e00560. [PMID: 32284868 DOI: 10.1002/rcr2.560] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]